Latest news with #Enchant
News.com.au
26-06-2025
- Entertainment
- News.com.au
Wild Secrets Satisfyer Enchant Air Pulse Rabbit Vibrator review
These products are hand-picked by our team to help make shopping easier. We may receive payments from third parties for sharing this content and when you purchase through links in this article. Product prices and offer details are not assured, and should be confirmed independently with the retailer. Learn more WARNING: Adult content. As the more intricately complicated of the sexes, it's no secret that vulva owners need more than one feature to tickle their tastebuds and tantalise them into orgasm. So when I discovered that Wild Secrets, the country's leading destination for sexual wellness online, had cosied up with the largest pleasure-tech powerhouse in the world, Satisfyer, to create a one-of-a-kind sex toy with both a vibrating shaft and suction-style clitoral stimulation, I couldn't wait to get my fingers on the Wild Secrets Enchant Air Pulse Rabbit Vibator. Because as a sex writer who's been lucky enough to have trailed some of the world's best sex toys, I don't say this lightly that if a device boasts dual functionality, run out and buy it because you won't be disappointed. And this world-first collab is no exception. Wild Secrets Enchant 9.1" Air Pulse Rabbit Vibrator - powered by Satisfyer. Picture: Wild Secrets Since Sex and the City first introduced generations of women to the powerful pleasure of a rabbit vibrator, the classic toy has gone through plenty of changes. But this latest update might just be my favourite yet. Wild Secrets has given its Enchant a glow up to feature more flexibility in the head and shaft, a sleep digital display so you never run out of power mid-pay, and upgraded to Satisfyer Pro 2 Air Pulse Technology. In other words, with its 12 internal vibration functions for your G-spot and 11 Air Pulse clitoral stimulation modes, it's the perfect package for those who love penetration alongside external pleasure. While it's got promises to blow users away (figuratively and physically I later learn), this device isn't just all about tech, because it feels like a luxury. Made from velvety soft and body-safe silicone, the curved rabbit vibrator is smooth as butter to touch and slip inside yourself – with a little help of water-based lube if you need. The only con I felt was that the clitoral stimulator, or what I call the clit sucker, didn't quite sit naturally on my most erogenous zone. But with a bit of hand-holding, I was able to shape the flexible head to my body and reach the areas where it was most needed. HOW WE TESTED THE WILD SECRETS ENCHANT 9.1' AIR PULSE RABBIT VIBRATOR In my world, a sex toy is never just for solo play and I love nothing more than bringing it into the bedroom with me. So when my long-distance boyfriend flew into town, I handed him the toy and the reins, giving him total control over my pleasure. With him in the driver's seat, I lay back on my bed while he flicked through the buttons and got familiar with our added extra. And then he delved right into it. WHAT WAS THE EXPERIENCE LIKE? I often find vibrators a tad tricky to manoeuvre, but with a slick of lube and my naked boyfriend beside me, it slid right in. Then my partner flicked the switch. Like an earthquake deep inside me, the Enchant began to emit waves of pleasure that grew with every level of pressure wave intensity and vibration function and trembled through my vaginal walls. Shaking with ecstasy that sent shivers down my arms, the power of not one but two independently controlled motors was almost too much to bear as I leant in and rode the waves of satisfaction. HOW POWERFUL WAS THE TOY? COULD IT STIMULATE AN ORGASM? With both the pressure wave intensity and G-spot vibration function at their highest peak, this is one hell of a powerful sex toy not to be underestimated. And while I don't usually orgasm from a vibrator alone, this double-whammy with its clit sucking action was enough to push me over the edge, sending me spiralling into a never-ending delight. DOES IT OFFER MULTIPLE OR VARIABLE SPEEDS? Yes, just in case I haven't shouted about this enough, the Enchant features 11 pressure wave intensities and 12 G-spot vibration functions which are all controlled on the digital display, as well as the charge level. Simply lay back and flick through the options until you find your perfect combo. IS THE ENCHANT USER FRIENDLY? It always takes me a while to get my head and hands around a new sex toy's functions, but once I've got a grip on how it works and exactly what will get me to climax, I'm a well-seasoned pro and the Enchant was very straight forward. IS IT EASY TO CLEAN? Absolutely. With its super smooth silicone and waterproof ability, the Enchant is super easy to wash down with water and gentle soap or an antibacterial toy cleaner after a messy session. Or better yet, take it into the shower with you and knock off two birds with one stone and then let it fully dry before putting it away (or you could keep it on your bedside table to use again and again later on …). HOW MUCH IS THE ENCHANT? The Enchant is $159.99 which I think is a steal for a two-in-one toy with a motor that gives you an orgasm like that. VERDICT: IS THE WILD SECRETS ENCHANT 9.1' AIR PULSE RABBIT VIBRATOR WORTH BUYING? While I had my reservations about an internal vibrator, being a girlie who loves clitoral stimulation, the Enchant blew my expectations out of the water. Soft and luxurious with the perfect balance between firm and flexible, this toy feels amazing against the skin, while the curved shape fits perfectly in the palm and against the body for satisfying sensations. But it's the suction-style clitoral stimulator that steals the show with its huge variety of patterns and intensities meaning there's something to suit every taste and mood. Whether you want a slow tease or want to go hard, a setting exists to send pleasure radiating through your entire body for a toe-curling, never-ending finish – solo or with a partner. As a sex and relationships writer, Ebony Leigh is Australia's answer to Carrie Bradshaw, if she was a Samantha. Inviting readers under the covers to share her erotic stories and blow the top of taboos with no subjects off limits, Leigh is your unrestricted pass into the scandalous sexploits of an insatiable 30-something.
Business Wire
26-06-2025
- Business
- Business Wire
Iambic Taps Lambda for Increased AI Compute as it Develops the Next Generation of Enchant, a Breakthrough AI Molecular Property Prediction Model for Drug Discovery
SAN JOSE, Calif.--(BUSINESS WIRE)--Lambda, the GPU cloud company founded by AI engineers, today announced that Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, has selected Lambda to provide an NVIDIA HGX B200 cluster to support the training of Enchant, its industry-leading model for molecular property prediction. Iambic's Enchant is a breakthrough multi-modal transformer model for predicting clinical and preclinical endpoints related to the drug discovery and development process. Enchant enables researchers to determine the viability of new drug molecules and make high-confidence predictions where data is most sparse, helping address the critical real-world challenge of understanding how novel drug candidates may affect a patient while still in the earliest stages of discovery. Iambic's recently announced Enchant v2 provides accurate predictions for dozens of biological, physiochemical, pharmacokinetic, metabolic, safety, and other properties essential for clinical success. 'With the release of Enchant v2, we demonstrated both the model's accuracy and scalability and we believe we can rapidly build on these gains through model scale alone,' said Matt Welborn, PhD, Iambic's VP of Machine Learning. 'We are expanding our successful relationship with Lambda to an NVIDIA HGX B200 cluster, which will accelerate this opportunity and the breadth of pre-clinical and clinical endpoints Enchant can predict, increasing the likelihood of a molecules' success in human studies and the efficiency of drug development.' Enchant's high-confidence predictions enable multi-parameter optimization for the design of potentially more effective medicines, program prioritization, and the design of clinical trials for the potentially rapid translation of novel medicines. Iambic researchers also demonstrated that in some cases Enchant can be a better predictor of in vivo drug clearance than in vitro experiments – a key advancement as regulators look for drug developers to broaden their use of in silico testing. Today, Enchant is the leading model in the field based on performance benchmarks across diverse molecular property prediction tasks. 'We're thrilled to deepen our partnership with Iambic, a leader in AI-driven drug discovery,' said Robert Brooks IV, Founding Team and VP, Revenue. 'By leveraging Lambda's 1-Click Clusters for rapid testing and validation, Iambic was able to seamlessly scale to an NVIDIA HGX B200 cluster to accelerate breakthroughs in life sciences.' To learn more about Lambda's cloud offerings for AI training and inference, click here. About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at About Lambda Lambda was founded in 2012 by AI engineers with published research at the top machine learning conferences in the world. Our goal is to become the #1 AI compute platform serving developers across the entire AI development lifecycle. We enable AI engineers to easily, securely and affordably build, test and deploy AI products at scale. Our product portfolio spans from on-prem GPU hardware to hosted GPUs in the cloud. Lambda's mission is to create a world where access to computation is as effortless and ubiquitous as electricity.
Yahoo
10-06-2025
- Business
- Yahoo
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO, June 10, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. "While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials," said Tom Miller, PhD, Iambic's co-founder and CEO. "Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas." Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. "Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals." The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@
Business Wire
10-06-2025
- Business
- Business Wire
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. 'While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials,' said Tom Miller, PhD, Iambic's co-founder and CEO. 'Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas.' Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. 'Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals.' The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at
CNBC
10-06-2025
- Business
- CNBC
26. Iambic Therapeutics
Founders: Tom Miller (CEO), Fred ManbyLaunched: 2020Headquarters: San Diego, CaliforniaFunding: $220 millionValuation: N/AKey Technologies: Artificial intelligence, cloud computing, deep neural networks/deep learning, generative AI, machine learning, robotics, quantum computingIndustry: BiotechPrevious appearances on Disruptor 50 list: 0 It can take 10-15 years for today's biopharmaceutical companies to bring new drugs all the way through discovery and clinical trial. San Diego-based Iambic Therapeutics' AI-driven platform can accelerate the pace of drug discovery and development, enabling drug development in just a few years. The company has novel medications in its pipeline to treat breast cancer and other HER2 cancers, and recently formed a research collaboration with pharmaceutical giant Lundbeck for a small molecule therapeutic to treat migraines. By predicting how its new molecules will interact with human systems, Iambic's technology can also reduce the need for clinical trials. The company was originally called Entos, and was founded when CEO Thomas Miller, a theoretical chemist and professor at California Institute of Technology, teamed up with longtime collaborator Fred Manby. In its first iteration, the company worked on making better chemical predictions across many industries and worked with companies including Toyota and Procter & Gamble. But the founders saw applications for their work in what's called small molecule drug discovery. Small molecule drugs, often synthesized chemically, target specific proteins or cellular pathways. Iambic's platform for drug discovery is called Enchant. The company says it provides high-confidence predictions in data-poor situations, such as early-stage and clinical-stage drug programs. "(Cancer) is an area of huge need," Miller told an interviewer for the California Institute of Technology in 2022. "It's an incredibly fast, quickly advancing disease. Many people are afflicted by it. There's many varieties of it. It is the combination of those things that means that if you have the ability to design a new drug, there's a way to … have a relatively fast timescale to advance that to the point where it's in human trials." Rather than selling its drug-discovery services and software to pharmaceutical companies, Iambic has focused on producing its own drugs. "Instead of running around, trying to convince people that this software is so great, and they should buy it, you can actually just use it and execute with it, and actually make better molecules. Then those molecules can stand on their own two feet," Miller said. In 2024, Iambic completed a B round of funding, with investors including OrbiMed, Nvidia and Sequoia Capital, and announced a collaboration with Nvidia, which has been teaming up as a venture investor with many startups across sectors using AI, including, for example, agtech Disruptor Carbon Robotics. Iambic also moved into a new headquarters in San Diego last year and took its headcount to about 100, enabling the company to run experiments on thousands of newly discovered molecules each week. It also announced an update to NeuralPLexer, which predicts protein-ligand structures, and published data in Nature Machine Intelligence showing that NeuralPLexer outperformed AlphaFold, the Nobel Prize in Chemistry winner developed by Google's DeepMind. Iambic also hired its first CFO, Michael Secora, who previously worked at publicly held Recursion.
